These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18181014)

  • 1. "Are you at risk for hereditary breast cancer?": development of a personal risk assessment tool for hereditary breast and ovarian cancer.
    Cohn WF; Jones SM; Miesfeldt S
    J Genet Couns; 2008 Feb; 17(1):64-78. PubMed ID: 18181014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
    Appel SJ; Cleiment RJ
    J Natl Black Nurses Assoc; 2015 Dec; 26(2):17-26. PubMed ID: 27045154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian.
    Hessock M; Brewer T; Hutson S; Anderson J
    Nurs Womens Health; 2021 Jun; 25(3):187-197. PubMed ID: 33933425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Communicating risk of hereditary breast and ovarian cancer with an interactive decision support tool.
    Rupert DJ; Squiers LB; Renaud JM; Whitehead NS; Osborn RJ; Furberg RD; Squire CM; Tzeng JP
    Patient Educ Couns; 2013 Aug; 92(2):188-96. PubMed ID: 23664232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "It's not if I get cancer, it's when I get cancer": BRCA-positive patients' (un)certain health experiences regarding hereditary breast and ovarian cancer risk.
    Dean M
    Soc Sci Med; 2016 Aug; 163():21-7. PubMed ID: 27376595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan.
    Bando H
    Breast Cancer; 2014 Nov; 21(6):656-63. PubMed ID: 23754181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
    Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD
    Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking the dissemination of a culturally targeted brochure to promote awareness of hereditary breast and ovarian cancer among Black women.
    Scherr CL; Bomboka L; Nelson A; Pal T; Vadaparampil ST
    Patient Educ Couns; 2017 May; 100(5):805-811. PubMed ID: 27866793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
    Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
    Shulman LP
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population.
    Dominguez FJ; Jones JL; Zabicki K; Smith BL; Gadd MA; Specht M; Kopans DB; Moore RH; Michaelson JS; Hughes KS
    Cancer; 2005 Nov; 104(9):1849-53. PubMed ID: 16136597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
    Vineyard MA; Daniels MS; Urbauer DL; Deavers MT; Sun CC; Boerwinkle E; Bodurka DC; Gershenson DM; Crawford J; Lu KH
    Gynecol Oncol; 2011 Feb; 120(2):229-32. PubMed ID: 21126756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.